Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07023081

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant

The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among adults, children, and infants, as well as the immunogenicity of 20vPnC among infants and children under 2 years of age in China. This vaccine will be given as per the age-specific dosing schedules among healthy adults, children and infants in China.

This study is seeking healthy participants of 6 groups:

* Group 1: Adults ≥18 to <50 years of age * Group 2: Children ≥2 to <6 years of age * Group 3: Children ≥12 months to <2 years of age * Group 4: Infants ≥7 to <12 months of age * Group 5: Infants ≥42 to ≤98 days of age * Group 6: Infants ≥42 to ≤98 days of age

All participants in Group 1 to 5, in this study will receive 20vPnC as per the age-specific dosing schedules:

* Group 1: participants will receive 1 dose of 20vPnC. * Group 2: participants will receive 1 dose of 20vPnC. * Group 3: participants will receive 2 doses of 20vPnC. Dose 2 will be given 56 to 70 days after Dose 1. * Group 4: participants will receive 3 doses of 20vPnC. Dose 2 will be given 28 to 56 days after Dose 1, and Dose 3 will be given at 365 to <455 days of age and at least 56 days after Dose 2. * Group 5: participants will receive 4 doses of 20vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to <455 days of age.

Participants in Group 6 will be randomized in a 1:1 ratio to received either 20vPnC or 13vPnC:

- Group 6: participants will receive 4 doses of 20vPnC or 13vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to <455 days of age.

The study will look at the experiences of people receiving the study vaccine. The study will also look at the immune response of some people receiving the study vaccine. This will help decide if the study vaccine is safe.

The total duration of taking part in the study from each group is:

* Participants in Group 1 and Group 2 will take part for about 6 months, with 6 visits. * Participants in Group 3 will take part for about 8 months, with 9 visits. * Participants in Group 4 will take part for about 12 months, with 8 visits. * Participants in Group 5 and 6 will take part for about 16 to 19 months, with 11 visits.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Pneumococcal Disease Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Pneumococcal Infections Streptococcal Infections

Age range

42 day–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key inclusion criteria:

  • Male or female participants:
  • Adults ≥18 to <50 years of age
  • Children ≥2 to <6 years of age
  • Children ≥12 months to <2 years of age
  • Infants ≥7 to <12 months of age
  • Infants ≥42 to ≤98 days of age
  • Healthy participants determined by clinical assessment and clinical judgment, to be eligible for the study.

Key exclusion criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention, or any diphtheria toxoid-containing vaccine.
  • History of microbiologically proven invasive disease caused by S pneumoniae.
  • Congenital, functional, or surgical asplenia.
  • Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt during study participation.
  • Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s).

Please refer to the study contact for further eligibility details.

Treatment and study plan

20vPnC

Biological

20vPnC vaccine

13vPnC

Biological

13vPnC vaccine

Primary outcomes

  1. Percentage of participants reporting prespecified local reactions within 7 days following each study intervention

    Time frame: Within 7 days of each study intervention

    Prespecified local reactions following each study intervention

  2. Percentage of participants reporting prespecified systemic events within 7 days following each study intervention

    Time frame: Within 7 days of each study intervention

    Prespecified systemic events following each study intervention

  3. Percentage of participants reporting adverse events (AEs) from the first study intervention through 1 month following the last study intervention administration

    Time frame: 1 month after the last vaccination

    AEs occurring through 1 month following the last study intervention administration for participants of adults ≥18 to <50 years of age at the time of consent, and children and infants ≥7 months to <6 years of age at the time of consent.

  4. Percentage of participants reporting AEs from the first study intervention through 1 month following the third study intervention.

    Time frame: From the first study intervention to 1 month after the third study intervention

    AEs occurring from the first study intervention through 1 month following the third study intervention in infants ≥42 to ≤98 days of age at the time of consent.

  5. Percentage of participants reporting AEs from the fourth study intervention to 1 month following the fourth study intervention.

    Time frame: From the fourth study intervention to 1 month after the fourth study intervention

    AEs occurring from the fourth study intervention to 1 month following the fourth study intervention in infants ≥42 to ≤98 days of age at the time of consent.

  6. Percentage of participants reporting serious adverse events (SAEs) throughout the study

    Time frame: From the first study intervention to 6 months after the last study intervention

    SAEs through 6 months following last study intervention

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHINESE ADULTS, CHILDREN, AND INFANTS

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 15, 2025
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.